Antiandrogen monotherapy in the management of advanced prostate cancer.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 9074906.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The utility of monotherapy with antiandrogens in prostate cancer is under investigation. Flutamide (Eulexin, Schering-Plough International) appears equally effective to castration in prolonging progression-free survival. Nilutamide (Anandron, Roussel) has been studied less widely, but may represent a valid treatment option in advanced prostate cancer. Preliminary results suggest that bicalutamide (Casodex, Zeneca Ltd) is as effective as castration in non-metastatic disease. Monotherapy with non-steroidal antiandrogens may offer successful palliative management of advanced prostate cancer with significant value in enhancing certain aspects of quality of life.
Medical subject headings
- Androgen Antagonists
- Antineoplastic Agents, Hormonal
- Imidazolidines
- Prostatic Neoplasms